financetom
Business
financetom
/
Business
/
Siemens Energy to cut 7,800 jobs in face of coal phase-out
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Siemens Energy to cut 7,800 jobs in face of coal phase-out
Feb 2, 2021 6:21 AM

Siemens Energy, which supplies turbines to the power sector, will cut 7,800 jobs to counter a drop in demand for new coal-fired energy stations that has also hit rivals General Electric and Mitsubishi Heavy Industries. Siemens Energy last year announced it would no longer bid in tenders to supply turbines to coal-fired power plants, responding to a weakening market as numerous governments around the world are phasing out the polluting fuel.

The jobs to be lost represent 8.5 percent of the company’s workforce. The bulk of the cuts will be implemented by 2023 and incur restructuring costs in a mid-to high-triple-digit million euro range for the fiscal years 2020 to 2023, it said.

”The energy market is significantly changing which offers us opportunities but at the same time presents us with great challenges,” Chief Executive Christian Bruch said. ”We will undertake these measures in the most socially responsible way possible.”

In a sector shaped by fierce rivalry, General Electric filed a lawsuit last month accusing a unit of Siemens Energy of using stolen trade secrets to rig bids for gas turbine contracts.

Bruch said Siemens Energy had received the lawsuit, adding it would carefully examine the claims.

Cost cuts also helped Siemens Energy, spun off from Siemens AG last year, swing to a net profit of 99 million euros ($119.5 million) in the first quarter of its fiscal year, compared with a loss of 195 million a year ago.

The company also holds a majority stake in Siemens Gamesa, the world’s second-largest wind turbine maker after Denmark’s Vestas, which is benefiting from a global shift towards renewable energy and away from fossil fuels.

($1 = 0.8282 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
G Mining Ventures Said Received Final Environmental Permit for Oko West Gold Project in Guyana
G Mining Ventures Said Received Final Environmental Permit for Oko West Gold Project in Guyana
Sep 2, 2025
08:56 AM EDT, 09/02/2025 (MT Newswires) -- G Mining Ventures ( GMINF ) on Tuesday said it has received a permit from Guyana's Environmental Protection Agency for the Oko West Gold Project. The permit, valid through July 2030, authorizes the construction and operation of Oko West, which is expected to create an average of 1,270 direct permanent jobs during its...
CareCloud Raises 2025 Revenue Guidance
CareCloud Raises 2025 Revenue Guidance
Sep 2, 2025
08:36 AM EDT, 09/02/2025 (MT Newswires) -- CareCloud ( CCLD ) said Tuesday that it has raised its revenue guidance for 2025 as a result of its acquisition of Medsphere Systems' business assets. The healthcare IT company said it now expects annual revenue of $116 million to $118 million, up from previous guidance of $111 million to $114 million. The...
Academy Sports and Outdoors Fiscal Q2 Adjusted Earnings Fall, Net Sales Rise
Academy Sports and Outdoors Fiscal Q2 Adjusted Earnings Fall, Net Sales Rise
Sep 2, 2025
08:26 AM EDT, 09/02/2025 (MT Newswires) -- Academy Sports and Outdoors ( ASO ) reported fiscal Q2 adjusted earnings Tuesday of $1.94 per diluted share, down from $2.03 a year earlier. Analysts polled by FactSet expected $2.14. Net sales for the quarter ended Aug. 2 were $1.60 billion, up from $1.55 billion a year earlier. Analysts surveyed by FactSet expected...
United Therapeutics Says Lung Disease Drug Tyvaso Meets Primary Endpoint in Pivotal Study
United Therapeutics Says Lung Disease Drug Tyvaso Meets Primary Endpoint in Pivotal Study
Sep 2, 2025
08:27 AM EDT, 09/02/2025 (MT Newswires) -- United Therapeutics ( UTHR ) said Tuesday that a pivotal study evaluating its nebulized Tyvaso inhalation solution for idiopathic pulmonary fibrosis has met its primary efficacy endpoint. The company said the treatment showed superiority over placebo in terms of absolute forced vital capacity by 95.6 mL from baseline to week 52 in patients...
Copyright 2023-2026 - www.financetom.com All Rights Reserved